Drug Type Small molecule drug |
Synonyms + [4] |
Target |
Mechanism PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), TNKS1 inhibitors(tankyrase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H24N6O |
InChIKeyGRPXLKXGJAGYSD-UHFFFAOYSA-N |
CAS Registry2055357-64-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Endometrial Cancer | Phase 2 | - | 01 Aug 2024 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | KR | 31 Aug 2022 | |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | 06 Dec 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | KR | 06 Dec 2017 | |
Pancreatic Cancer | Phase 2 | KR | - | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | KR | 30 Mar 2022 | |
Secondary malignant neoplasm of pancreas | Phase 1 | KR | 30 Mar 2022 | |
Colorectal Cancer | Phase 1 | - | - | |
Colorectal Cancer | Phase 1 | - | - |
NCT04335604 (ASCO2021) Manual | Phase 1 | 62 | (dose escalation) | (bstldqjlta) = alaiijbqdt trlturzbzy (rtpycerkba ) View more | Positive | 20 May 2021 | |
(dose escalation) | (yhxaifbajw) = xtdrbaqotu wtkeiixmju (aqwavawsyj ) View more |